

## CORPORATE NEWS

### **AlzChem Group AG: Consistent growth course supported by Annual General Meeting**

- **Dividend of EUR 0.77 per share resolved, corresponds to 40% of consolidated net income**
- **Strong start to fiscal year 2021**
- **Achievement of full-year guidance expected at upper end**

**AlzChem Group AG**  
Dr.-Albert-Frank-Str. 32  
83308 Trostberg  
Germany

[www.alzchem.com](http://www.alzchem.com)

**Sabine Sieber**  
Investor Relations

T +49 8621 86-2888  
F +49 8621 86-502888  
[ir@alzchem.com](mailto:ir@alzchem.com)

Trostberg, May 12, 2021 – “I am very pleased with the vote of confidence by our shareholders to both support our successful growth course and confirm our dividend policy through the resolutions at today’s virtual Annual General Meeting. We will continue to implement exciting projects in 2021 that will allow our company to grow further in terms of sales and profits,” explained Andreas Niedermaier, CEO of AlzChem Group AG. He cited a number of examples of this: “Before the end of this year, we will launch EMINEX<sup>®</sup>, a product that can raise climate protection in agriculture to a new level globally. In the case of our important product of the future, Creamino<sup>®</sup>, we will be judged by the success of our new sales strategy in 2021, because the market is beginning to turn around with the pandemic possibly subsiding, and there are clear indicators that we will soon be able to show significantly more dynamic growth rates again with correspondingly positive margin effects. A third example is our expanded nitrile capacities, which we have expanded by a further 50% through investments of around EUR 12 million and which will be fully available before the end of the second quarter of 2021. This could generate additional annual sales of EUR 10 to 20 million – depending on the product mix. And this product mix has plenty to offer: intermediates for the pharmaceutical and biocide industries, environmentally friendly pigments in automotive coatings, and UV absorbers in sun creams will noticeably support our growth,” says Niedermaier.

This year, AlzChem Group AG aims to grow sales to up to EUR 400 million (2020: EUR 379.3 million) and EBITDA to a stable to slightly increasing result of up to EUR 57 million (2020: EUR 53.8 million). Following the very good performance of the financial year to date, the forecast is expected to be achieved rather at the upper end.

The Annual General Meeting 2021 of AlzChem Group AG today resolved to distribute a dividend of EUR 0.77 per share to be paid on May 18, 2021. This corresponds to a distribution volume of EUR 7.8 million, or just under 40% of the consolidated net income of EUR 19.9 million achieved in 2020. AlzChem Group AG’s dividend policy is to distribute between 30% and 50% of net income each year.

All other resolutions at today's Annual General Meeting were also passed by a large majority, including the discharge of the Management Board and Supervisory Board, the election of the auditor, the approval of the remuneration system for the Management Board and the remuneration of the Supervisory Board members.

The voting results of the Annual General Meeting can be viewed on the website at <https://www.alzchem.com/en/investor-relations/annual-general-meeting>.

### **About AlzChem**

AlzChem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. AlzChem benefits in particular from the three very different global megatrends of sustainability, population growth and healthy aging. AlzChem products offer attractive solutions in a wide range of applications.

The company sees interesting growth prospects for itself above all in the fields of human and animal nutrition, pharmaceuticals, agriculture, fine chemicals, metallurgy and renewable energies. The broad product range includes, for example, dietary supplements, plant growth regulators and precursors for corona tests.

The company employs around 1,630 people at four production sites in Germany and Sweden, and at two sales companies in the USA and China. In 2020, AlzChem generated consolidated sales of around EUR 379 million and EBITDA of around EUR 53.8 million.